Year: 2018
Language: Traditional Chinese
Author(s): Jenny Goudemand, Manuel Carcao
Format: Document
Also Available In: English, Spanish
This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for the translation or for any errors or changes to content from the original English edition. Patient organizations interested in translating a WFH resource must first obtain permission from the WFH, available here.
Inhibitors are a serious complication of hemophilia caused by an immune response to clotting factor concentrates. Treatment of inhibitors is one of the biggest challenges in hemophilia care today. This primer explains our current understanding of how and why inhibitors form, reviews the established approaches to managing inhibitors, and looks ahead to some potential future developments in the field.
La principale complication du traitement et de la prévention des hémorragies est le développement d’anticorps inhibiteurs contre le facteur VIII
The development of inhibitory antibodies to therapeutic factor VIII (FVIII) in up to 40% of people with severe hemophilia A
The development of inhibitory antibodies to therapeutic factor VIII (FVIII) in up to 40% of people with severe hemophilia A
El desarrollo de anticuerpos inhibidores del factor VIII terapéutico (FVIII) en hasta el 40% de las personas con hemofilia A
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Traditional Chinese Los
Also Available In: Japanese This resource has also been translated into the following language, with permission from the WFH, by